Trials / Completed
CompletedNCT04436107
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study of Bruton Tyrosine Kinase (BTK) Inhibitor, Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety, tolerability, and efficacy of zanubrutinib in combination with lenalidomide in participants with R/R DLBCL
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | 160 mg administered orally twice daily (BID) |
| DRUG | Lenalidomide | Administered orally on Days 1-21 each cycle followed by a mandatory 7-day drug-free interval. |
Timeline
- Start date
- 2020-09-11
- Primary completion
- 2024-03-28
- Completion
- 2024-03-28
- First posted
- 2020-06-17
- Last updated
- 2025-05-23
- Results posted
- 2025-05-23
Locations
10 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04436107. Inclusion in this directory is not an endorsement.